Corline Biomedical AB (CLBIO ST) stock market data APIs
kr10.9487
-0.11(-1%)
as of April 29, 2025
Corline Biomedical AB Financial Data Overview
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries. The company was incorporated in 1991 and is based in Uppsala, Sweden.
Prev. Close
10.9487
Open
10.8351
High
11.173
Low
10.6175
52 wk Range
5.98-13.75
Market Cap
267 M
Shares Outstanding
24 491 K
Revenue
17 272 K
EPS
-0.6217
Beta
0.426
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Corline Biomedical AB data using free add-ons & libraries
Get Corline Biomedical AB Fundamental Data
Corline Biomedical AB Fundamental data includes:
- Net Revenue: 17 272 K
- EBITDA: -13 079 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-17
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Corline Biomedical AB News
New
Corline Biomedical AB publicerar delårsrapport för det tredje kvartalet 2023
Corline Biomedical AB (”Corline”) publicerar härmed delårsrapporten för perioden januari till september 2023. Nedan följer en kort sammanfattning av delårsrapporten. Fullständig rapport finn...
12-månadersuppföljning stödjer säkerhet och indikerar positiv behandlingseffekt av Renaparin®
Corline Biomedical AB (”Corline”) meddelar härmed resultat efter uppföljning i 12 månader av behandlade patienter i RENAPAIR 01 samt vid jämförelse med transplanterade parnjurar. I septembe...
Corline Biomedical AB: Erhåller BfArM-godkännande att starta fas 2-studie
Corline Biomedical AB (”Corline” eller ”Bolaget”) meddelar att Tysklands hälsovårdsmyndighet BfArM godkänner start av fas 2-studien RENAPAIR 02 i enlighet med den ansökan Bolaget inlämna...
Rättelse: Corline Biomedical AB offentliggör delårsrapport för perioden januari till juni 2023
I tidigare pressmeddelande meddelades felaktig avtalslängd vid referens till viktiga händelser under perioden. Nedan följer rättelse av tidigare pressemeddelande i sin helhet. Corline Biomedical ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
